Shots:
- The UK’s MHRA has approved Leqembi (IV, Q4W) as a maintenance therapy for early Alzheimer’s pts after completing 18mos. of Q2W Leqembi treatment
- Leqembi is approved in 51 countries for early AD & under review in 9, while the Q4W maintenance is approved in the UK, China, the US, & others, with 4 applications filed & more underway. A rolling US FDA sBLA for Leqembi Iqlik (SC) was also initiated in Sep 2025
- Leqembi was developed by BioArctic, with Eisai leading clinical development, regulatory submissions, & global commercialization, & both companies jointly commercializing it in the Nordic region
Ref: BioArctic | Image: Eisai & BioArctic | Press Release
Related News:- Eisai and Biogen Report the Health Canada’s Approval of Leqembi (Lecanemab) to Treat Alzheimer’s Disease
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
